Your Health, We Care
Another NameBraftovi,LuciEncor,康奈非尼
IndicationsIt is indicated for the treatment of unresectable or metastatic melanoma, colorectal cancer, and non-small cell lung cancer with BRAF V600E or V600K mutations, and must be used in conjunction with spe
Reg No.08 L 1184/24
Inspection NO.2011-24
Encorafenib produced by Lucius Pharmaceuticals has shown good efficacy and safety, providing a clinically valuable treatment option for patients with specific BRAF mutations.
Below is an overview of key information about Encorafenib.
The main active ingredient is encorafenib, a kinase inhibitor.
It is indicated for adult patients with BRAF V600E or V600K mutations confirmed by an FDA-approved testing method.
The recommended dosage varies by indication and combination therapy regimen, typically 300 mg or 450 mg orally once daily. Reference article: Dosage and Administration of Encorafenib
Pregnant women: Contraindicated.
Lactating women: Should discontinue breastfeeding.
Elderly patients: No dosage adjustment is required.
Patients with mild to moderate hepatic or renal impairment: Usually no dosage adjustment is needed.
There is no specific antidote for encorafenib overdosage. Supportive treatment should be administered, and hemodialysis may be ineffective.
The medication should be stored in its original bottle, tightly sealed, at room temperature. Protect from moisture, and do not remove the desiccant inside the bottle.
Pharmacokinetically, encorafenib is mainly metabolized by CYP3A4, with a half-life of approximately 3.5 hours. High-fat meals may reduce its absorption.
FDA，2025.03
